[one week king] "cost performance" becomes the highest pursuit of the hospital, affecting the drug price of the whole industry; the second batch of centralized procurement is launched nationwide; the "one vote system" is coming soon; the first domestic HPV vaccine is on the market

This week, "cost performance" becomes the highest pursuit of the hospital, and enterprises need to respond to changes in advance; the second batch of centralized procurement is launched nationwide, "bloody" competition is coming again; "one vote system" is coming, are enterprises ready? The first domestic HPV vaccine is listed, and the price is the biggest advantage; the "cost-effective" news of the General Administration has become the highest pursuit of the hospital, and the enterprise needs to respond to the change in advance On January 2, the official website of the national health and Health Commission posted the notice on printing and distributing the regulations on the management of internal price behavior of medical institutions, which was clearly proposed in the document jointly issued with the Chinese medicine administration The notice indicates that the regulation is applicable to all kinds of public medical institutions at all levels, and non-public medical institutions can also refer to it; the internal price behavior management of medical institutions refers to the internal management of price behaviors such as medical service items, drugs and medical consumables in medical institutions' diagnosis and treatment activities The document also specifically requires medical institutions to establish the management system of medical service cost measurement and cost control, the management system of medical service price adjustment, the management system of new medical service price items, the price publicity system, etc., emphasizing that the president is responsible for the price management of the hospital, and the relevant departments will regularly check the cost of patients, and correct the irregular charges of the hospital And punishment, emphasis on cost calculation, and clear the hospital account book At the same time, with the acceleration of DRG, cost performance has become the primary consideration of the country and hospitals, and also the key point of enterprise competition From the perspective of controlling the growth of medical expenses, it is urgent to gradually establish DRG and pay for performance mechanism Brief comment: the purpose of price reduction is obvious to all The implementation of DRG will certainly bring a brand-new "earthquake" to the pharmaceutical industry Enterprises need to sort out product lines synchronously according to the market situation, cooperate with DRG to create product mix for a certain disease group or field according to the fixed amount payment mode of each similar disease group to cope with the change, no matter whether they can win the market or not, the first step is for enterprises at least What must be done! The second batch of centralized procurement was launched nationwide, and "bloody" competition came again on December 29 Shanghai Sunshine pharmaceutical purchasing network released the announcement of the joint procurement office for centralized procurement and use of drugs of the state organization (hereinafter referred to as the announcement), and the second batch of centralized procurement and use of drugs of the State Organization officially kicked off The announcement announced a new round of official shortlist of 33 varieties, and according to the work deployment of the volume procurement, the procurement scope will directly cover 31 provinces across the country Compared with the previous versions, metformin sustained-release dosage form and metformin oral regular release dosage form were removed This centralized purchase announced the changes of the most effective application and quotation, the highest purchase proportion to 80%, the extended purchase cycle to 3 years, and the number of shortlisted enterprises to 6 In this way, although the number of shortlisted and winning enterprises will be increased, the vested interests may not be more than the last centralized purchase, and the average share of winning enterprises may face a downward trend Brief comment: many successful bidders are also a double-edged sword On the one hand, they can guarantee a certain degree of balance between price and supply; on the other hand, the intensity of competition may also be weakened, and enterprises may obtain a huge market with a small price cut But in any case, the competition is still increasing, especially some small enterprises will win the bid with very low price competition risk, many enterprises will also pay a painful market price According to the work arrangement of centralized procurement, the bid opening will be held on January 17, 2020 to produce the result of the proposed winning bid, and the more "bloody" competition will begin soon! On December 30, the medical administration and medical management office of Wuhan Health Committee issued the emergency notice on the treatment of pneumonia of unknown causes According to the notice, some medical institutions in Wuhan have seen pneumonia patients of unknown causes The notice requires all medical institutions to track and count the treatment situation in time, and report to the superior timely as required According to the expert consultation, no obvious human to human phenomenon has been found in the investigation so far, and no infection has been found in the medical staff According to the current situation, 27 cases have been found, 7 of which are seriously ill, the rest are stable and controllable, and 2 cases are expected to be discharged in the near future The local authorities are also testing the pathogen and investigating the cause of infection At the same time, the stock market of the pharmaceutical industry is in turmoil, and the stock prices of almost all vaccine manufacturers have risen It can be seen that the impact of this event is quite deep! Brief comment: up to now, many details are not clear As a spectator, we should restrain ourselves We should never spread false information and cause unnecessary panic The document also shows that once the laboratory results come out, they will be publicized as soon as possible, and relevant treatment plans will come out We should wait and see the changes The case of gene editor's son was adjudicated! Relevant personnel's illegal medical practice judgment issued On December 30, the case of gene editing baby was adjudicated Due to the fact that three defendants failed to obtain the qualification of doctor practice and pursued fame and profit, they deliberately violated the relevant regulations of the state on scientific research and medical management, exceeded the bottom line of scientific research and medical ethics, applied gene editing technology to human assisted reproductive medicine, and disturbed the order of medical management The circumstances were serious, and their behaviors constituted the crime of illegal medical practice Among the three defendants, he Jiankui was sentenced to fixed-term imprisonment of three years and a fine of 3 million yuan; Zhang Renli was sentenced to fixed-term imprisonment of two years and a fine of 1 million yuan; Qin Jinzhou was sentenced to fixed-term imprisonment of one year and six months, suspended for two years and a fine of 500000 yuan The competent science and technology department and the administrative department of health and health respectively instruct the relevant units to improve the scientific research and medical management system and strengthen the supervision and management of relevant employees Many netizens agreed with the decision, saying: "gene editors will pollute the entire human gene pool, and the consequences may change the entire human gene history I hope that many scientists will recognize the consensus of the academic community, and do not want to violate the character's biological ethics because of their curiosity and conquest." "One vote system" is coming Are enterprises ready? On December 30, Gansu provincial drug and medical consumables centralized purchase network released the notice on publicity of one vote determination result of "two vote system" for drug purchase and sale (the ninth batch) According to the notice, according to the implementation plan of "two ticket system" for drug procurement of public medical institutions in Gansu Province (Trial), the notice on issues related to "two ticket system" for drug procurement of public medical institutions in Gansu Province issued by the original provincial health and Family Planning Commission and the notice on declaration items identified as one ticket in the "two ticket system" for drug purchase and sale issued by the Provincial Medical Security Bureau, it has been strictly enforced We hereby publicize the enterprise and product information approved in the ninth batch of audit It is mentioned that the four situations will be regarded as "one vote system" The wholly-owned or holding commercial companies (only one commercial company in China) established by pharmaceutical manufacturers or group enterprises integrating science, industry and trade that only sell their own (Group) pharmaceuticals, the domestic general agent of overseas pharmaceuticals (only one domestic general agent in China), and the production and operation entrusted by the holders of pharmaceutical listing licenses A group type circulation enterprise According to the analysis of relevant people, for example, according to the document of the State Council, except Gansu Province, there is the possibility of implementing "one vote system" in many places, and it may only be a matter of time before it is implemented nationwide Brief comment: the so-called "one vote system" means that the manufacturer's drugs directly arrive at the designated medical institutions (hospitals and pharmacies) for medical insurance to issue an invoice There is no intermediate agent business, and the manufacturer's payment is directly settled with the medical insurance fund Similar to the slogan "there is no middleman to earn the difference" of "melon seeds used car", the implementation of one vote system may greatly reduce the unit price of drugs, but it may also indirectly cause certain challenges to the cost of drug manufacturers I wonder if many enterprises are ready? Enterprise information is the first domestic HPV vaccine to be listed, and the price is the biggest advantage On December 31, 2019, the State Drug Administration approved the listing registration application of Xiamen Wantai Canghai Biotechnology Co., Ltd.'s bivalent human papillomavirus vaccine (E.coli) (trade name: Xinkening cecolin) The drug is the first approved domestic HPV vaccine, which is suitable for women aged 9-45 At present, there are three kinds of HPV vaccines on the market in the world, namely, the bivalent vaccine for HPV16 and 18 produced by GlaxoSmithKline, the bivalent vaccine for HPV6, 11, 16 and 18 produced by MSD, and the bivalent vaccine for HPV6, 11, 16, 18, 31, 33, 45, 52 and 58 produced by MSD The approved bivalent human papillomavirus vaccine (e Brief comment: Congratulations, China has its own cervical cancer vaccine, and its biggest competitive advantage in China should be determined by its pricing standard According to Xiamen Wantai news, Xinkening's price is 329 yuan / piece, women aged 9-14 only need to be vaccinated 2 times, and women aged 15-45 only need to be vaccinated 3 times The product is now ready to be put into production Compared with nine price HPV vaccine, the price is about 1300 yuan / shot, and four price HP vaccine The price of the vaccine is about 800 yuan / shot, and the price of the bivalent HPV vaccine is about 600 yuan / shot It seems that the domestic vaccine has great advantages After all, the foreign HPV vaccine is not affordable for every Chinese woman Gv-971 was listed on the market In the face of doubt, ganlute sodium capsule (phase 9, code: gv-971), an original Chinese new drug for Alzheimer's disease (AD), was officially listed in China on December 29, 2019 The 22-year-old Chinese original drug is the world's first approved drug for Alzheimer's disease since 2003 It is also one of the six used in clinical treatment in the world for more than 100 years But there are also a variety of disputes Therefore, on December 29, Xiao Shifu, the main inventor, clinical trial researcher and the head of the enterprise that funded the research, focused on the media for the first time to explain some social doubts about the drug It is claimed that the international requirements for the second phase clinical trial observation are at least 3 months, and the third phase clinical observation is at least 6 months However, the 3-phase clinical observation time of 9 months completed by gv-971 completely met the requirements And the guidelines for clinical trials of Alzheimer's disease drugs issued by the domestic regulatory authorities do not require two positive three-phase clinical trials The clinical trials are also in accordance with the requirements of "first pass", and next, gv-971 will carry out the international multi center clinical phase III trial Information source: Yaozhi news, Sina Pharmaceutical News, sepilan, e pharmaceutical manager, pharmaceutical economic news, China Pharmaceutical News, etc.; responsible editor | penicillin statement: This article is the integrated content of yaozhi.com, the copyright belongs to the original author, and the purpose of reprint is to transmit more information, which does not represent the view of this platform If you are involved in the work content, copyright and other questions, please contact the official account message We will delete the content at the first time.